This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), provides $831,583 to characterize microvascular impairment in adults with elevated genetic risk for Alzheimer's disease. The long-term goal is to elucidate physiological mechanisms through which the APOE-E4 genotype contributes to microvascular impairment, white matter lesion burden, and associated cognitive decline. The research will enroll a cohort of 40-80 year old adults at varying Alzheimer's risk based on APOE genotype to investigate the relationships between venous hyperintense signal, cerebral blood flow, oxygen extraction efficiency, and white matter lesion burden. Successful completion may inform development of therapeutics to mitigate microvascular contributions to cognitive decline in APOE pathology and identify hemodynamic biomarkers for earlier risk stratification. The project period runs from Mar 2025 to Jan 2030.
Generated 4/1/25, 4:06 AM